Pharmacokinetic/Pharmacodynamic Study of Doripenem in Febrile Neutropenic Patients
Status:
Completed
Trial end date:
2012-02-01
Target enrollment:
Participant gender:
Summary
Primary: To determine the serum pharmacokinetics (PK) of doripenem in febrile neutropenic
patients.
Secondary: Monte Carlo Simulations Tested Against Various Gram-negative Isolates and Reported
as Probability of Target Attainment (40% Time (fT)> minimum inhibitory concentration (MIC))